Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells

Cancer Immunology, Immunotherapy

Volumn 56, Issue 12, 2007, Pages 1911-1920

  Tita Nwa, Freddy ^a   Moldenhauer, Gerhard ^b   Herbst, Markus ^a   Kleist, Christian ^a   Ho, Anthony D ^a   Kornacker, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Adoptive immunotherapy; Bispecific antibody; Cytokine induced killer cells; Non Hodgkin's lymphoma; Targeted immunotherapy

Indexed keywords

BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD19XCD5 ANTIBODY; CD3 ANTIGEN; CD5 ANTIGEN; CYTOKINE; HD37XT5.16 ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY PRODUCTION; ANTIGEN BINDING; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY; EFFECTOR CELL; EX VIVO STUDY; FAST PROTEIN LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; KILLER CELL; LYMPHOMA CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; T LYMPHOCYTE;

ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD19; ANTIGENS, CD5; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; T-LYMPHOCYTES;

EID: 34848850135     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0333-0     Document Type: Article

References (36)

1. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181:71-77
2. Baeuerle PA, Kufer P, Lutterbuse R (2003) Bispecific antibodies for polyclonal T-cell engagement. Curr Opin Mol Ther 5:413-419
3. Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake PD, Diehl V, Tesch H (1993) Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 82:1803-1812
4. Bohlen H, Manzke O, Patel B, Moldenhauer G, Dorken B, von Fliedner V, Diehl V, Tesch H (1993) Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 53:4310-4314
5. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF et al (1995) Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441-444
6. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM, Eggermont AM, Goey SH, Gratama JW, Lamers CH et al (1995) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87:1463-1469
7. Cochlovius B, Kipriyanov SM, Stassar MJ, Christ O, Schuhmacher J, Strauss G, Moldenhauer G, Little M (2000) Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. J Immunol 165:888-895
8. Csoka M, Strauss G, Debatin KM, Moldenhauer G (1996) Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody. Leukemia 10:1765-1772
9. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dorken B (1997) Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol 159:3808-3815
10. de Gast GC, Haagen IA, van Houten AA, Klein SC, Duits AJ, de Weger RA, Vroom TM, Clark MR, Phillips J, van Dijk AJ et al. (1995) CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 40:390-396
11. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438-441
12. Haagen IA, de Lau WB, Bast BJ, Geerars AJ, Clark MR, de Gast BC (1994) Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol Immunother 39:391-396
13. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS (1998) Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92:3318-3327
14. Kipriyanov SM, Moldenhauer G, Strauss G, Little M (1998) Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer 77:763-772
15. Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, Hensel M, Ho AD (2006) Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int J Cancer 119:1377-1382
16. Kroesen BJ, Bakker A, van Lier RA, The HT, de Leij L (1995) Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28. Cancer Res 55:4409-4415
17. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS (2005) A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:181-187
18. Lu PH, Negrin RS (1994) A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153:1687-1696
19. Manzke O, Titzer S, Tesch H, Diehl V, Bohlen H (1997) CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma. Cancer Immunol Immunother 45:198-202
20. Marme A, Strauss G, Bastert G, Grischke EM, Moldenhauer G (2002) Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 101:183-189
21. Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS (1995) Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 86:3493-3499
22. Pezzutto A, Dorken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA (1987) CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol 138:2793-2799
23. Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98:2526-2534
24. Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS (2002) Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. Cancer Res 62:5785-5791
25. Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, Leo E, Bargou R, Murthy K, Baeuerle PA (2006) T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 55:503-514
26. Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG (1997) Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 74:51-56
27. Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS (1994) Propagation of large numbers of T cells with natural killer cell markers. Bri J Haematol 87:453-458
28. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21:1673-1679
29. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139-149
30. Segal DM, Weiner GJ, Weiner LM (1999) Bispecific antibodies in cancer therapy. Curr Opin Immunol 11:558-562
31. Strasser A (1995) Apoptosis: death of a T cell. Nature 373:385-386
32. van Spriel AB, van Ojik HH, van De Winkel JG (2000) Immunotherapeutic perspective for bispecific antibodies. Immunol Today 21:391-397
33. Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA (2001) Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 7:532-542
34. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS (2004) Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103:3065-3072
35. Verneris MR, Kornacker M, Mailander V, Negrin RS (2000) Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother 49:335-345
36. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83:261-266